EnBiotix is developing therapies to improve the lives of patients with chronic respiratory infections and other rare diseases. These therapies are currently investigational, and have not been approved by the US Food and Drug Administration. At present, our primary focus is conducting clinical trials to demonstrate the efficacy and safety of these therapies. We encourage patients, when possible, to participate in our clinical trials – enrollees in these trials are closely monitored and receive personalized care from clinical trial staff while under treatment.
Expanded Access (and Compassionate Use) can allow patients with an critical condition to receive an investigational outside of a clinical trial, but only when no alternative therapy options are available. As such, participation in our clinical trials is currently the only way to be treated with our investigational therapies. Please contact EnBiotix directly at firstname.lastname@example.org with questions. We will respond to all queries as quickly as possible. Per the 21st Century Cures Act, EnBiotix may revise this policy at any time.